Olumiant
| Chemical Name | baricitinib |
| Dosage Form | Tablet (oral; 2 mg, 1 mg) |
| Drug Class | Kinase inhibitors |
| System | Musculoskeletal |
| Company | Eli Lilly and Company |
| Approval Year | 2018 |
Indication
- Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.